U.S. markets closed

Jazz Pharmaceuticals plc (JAZZ)

NasdaqGS - NasdaqGS Real Time Price. Currency in USD
Add to watchlist
Visitors trend2W10W9M
141.90+1.75 (+1.25%)
At close: 4:00PM EDT
Full screen
Trade prices are not sourced from all markets
Gain actionable insight from technical analysis on financial instruments, to help optimize your trading strategies
Chart Events
Bullishpattern detected
Double Moving Average Crossover

Double Moving Average Crossover

Performance Outlook
Previous Close140.15
Open141.13
Bid141.57 x 1200
Ask141.90 x 800
Day's Range140.49 - 143.59
52 Week Range86.88 - 154.24
Volume6,595,182
Avg. Volume786,267
Market Cap7.87B
Beta (5Y Monthly)1.27
PE Ratio (TTM)60.23
EPS (TTM)2.36
Earnings DateNov 03, 2020 - Nov 09, 2020
Forward Dividend & YieldN/A (N/A)
Ex-Dividend DateN/A
1y Target Est165.67
Fair Value is the appropriate price for the shares of a company, based on its earnings and growth rate also interpreted as when P/E Ratio = Growth Rate. Estimated return represents the projected annual return you might expect after purchasing shares in the company and holding them over the default time horizon of 5 years, based on the EPS growth rate that we have projected.
Fair Value
XX.XX
Overvalued
-12% Est. Return
Research that delivers an independent perspective, consistent methodology and actionable insight
Related Research
View more
  • JAZZ vs. ZTS: Which Stock Is the Better Value Option?
    Zacks

    JAZZ vs. ZTS: Which Stock Is the Better Value Option?

    JAZZ vs. ZTS: Which Stock Is the Better Value Option?

  • Jazz Pharmaceuticals Launches Initiative to Help Educate People Living with Rare Form of Leukemia
    PR Newswire

    Jazz Pharmaceuticals Launches Initiative to Help Educate People Living with Rare Form of Leukemia

    Jazz Pharmaceuticals plc (Nasdaq: JAZZ) today announced the launch of Find the Right Fit (FindTheRightFit-sAML.com), a U.S. patient education program developed in consultation with the Myelodysplastic Syndromes (MDS) Foundation, Inc. and the Cancer Support Community focused on empowering people affected by secondary acute myeloid leukemia (sAML) and MDS.

  • Jazz Pharmaceuticals Announces New Sleep Health Collaboration
    PR Newswire

    Jazz Pharmaceuticals Announces New Sleep Health Collaboration

    Jazz Pharmaceuticals plc (Nasdaq: JAZZ) today announced its support of the American Heart Association's sleep health educational content aimed at improving the health and well-being of those struggling with healthy sleep or those living with sleep disorders. As part of the initiative, the Association, with financial support from Jazz, will create educational multimedia content that will be available at www.heart.org/en/health-topics/sleep-disorders.